Importance of Early Effective Treatment of MDD

EP: 1.Unmet Needs in Treatment of MDD

EP: 2.MDD Treatment Landscape

EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD

EP: 4.Burden of Treatment Failure in MDD

Now Viewing

EP: 5.Importance of Early Effective Treatment of MDD

EP: 6.Evaluating MDD Treatment Attributes

EP: 7.Considerations for Newly Launched MDD Treatments

EP: 8.Healthcare Disparities Within Major Depressive Disorder

EP: 9.MDD Treatment Disparities Across Patient Populations

EP: 10.Social Determinants of Health in MDD

EP: 11.Impact of COVID-19 on Demand for Mental Health Services

EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)

EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2

EP: 14.Social Determinants of Health in MDD: Part 2

EP: 15.Population Health Approach in MDD

EP: 16.Factors Affecting MDD Treatment Adherence

EP: 17.Supporting Adherence for Patients with MDD

EP: 18.Aligning MDD Treatment Goals for Payers and Patients

EP: 19.The Impact of Early Effective Treatment in MDD

EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD

Michael Rothrock, MBA, MHA: I’d like to build on the last answer by Dr Cannon. He mentioned the need for additional behavioral therapists, and I don’t disagree. COVID-19 has accelerated the number of patients looking for help. Telehealth has definitely allowed a little more convenience and uptake in behavioral health introduction, and maybe we’re removing some of the stigma associated with depression by allowing that one-on-one conversation. But as he alluded to, getting that interaction early and finding the right drug should provide the best outcome for the patient. [Doctors] may be able to intervene to say: “This drug may not be working, we should have seen something. Let’s write you a new prescription. Let’s minimize the cycling of trial and error of different medications.”

Getting them early treatment and getting them accurately and effectively treated with cognitive behavioral therapy is going to promote the best outcome and the long-term goal of minimizing the relapses of MDD [major depressive disorder].

H. Eric Cannon, PharmD, FAMCP: When we talk about early treatment options and getting needed treatment quickly, we sometimes discount the impact of failing that first choice or second choice. Each time it fails, the impact on the patient compounds. The sooner we can get a patient on effective treatment where they start to notice some benefit early on, the more the overall outcome for the patient is greatly improved.

Transcript edited for clarity.